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Abstract
Background: Major depressive disorder (MDD) is an independent risk factor for cardiovascular disease (CVD); the presence
of MDD symptoms in patients with CVD is associated with a higher incidence of cardiac complications following acute
myocardial infarction (MI). Stress-hemoconcentration, a result of psychological stress that might be a risk factor for the
pathogenesis of CVD, has been studied in stress-challenge paradigms but has not been systematically studied in MDD.
Methods: Secondary analysis of stress hemoconcentration was performed on data from controls and subjects with mild to
moderate MDD participating in an ongoing pharmacogenetic study of antidepressant treatment response to desipramine
or fluoxetine. Hematologic and hemorheologic measures of stress-hemoconcentration included blood cell counts,
hematocrit, hemoglobin, total serum protein, and albumin, and whole blood viscosity.
Findings: Subjects with mild to moderate MDD had significantly increased hemorheologic measures of stress-
hemoconcentration and blood viscosity when compared to controls; these measures were correlated with depression severity.
Measures of stress-hemoconcentration improved significantly after 8 weeks of antidepressant treatment. Improvements in
white blood cell count, red blood cell measures and plasma volume were correlated with decreased severity of depression.
Conclusions: Our secondary data analyses support that stress-hemoconcentration, possibly caused by decrements in plasma
volume during psychological stress, is present in Mexican-American subjects with mild to moderate MDD at non-challenged
baseline conditions. We also found that after antidepressant treatment hemorheologic measures of stress-hemoconcentration
are improved and are correlated with improvement of depressive symptoms. These findings suggest that antidepressant
treatment may have a positive impact in CVD by ameliorating increased blood viscosity. Physicians should be aware of the
potential impact of measures of hemoconcentration and consider the implications for cardiovascular risk in depressed patients.
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Introduction
Cardiovascular disease (CVD) risk has been linked to several
emotional and psychological factors, including stress and depression.
Mental stress can elicit acute coronary events and is considered a risk
factor for CVD [1]. Depressive symptoms, which are common
among patients with ischemic heart disease and those recovering
from an acute myocardial infarction (MI) [2,3] are associated with an
increased risk of CVD, MI, and cardiac mortality [3–7] In patients
with CVD, the presence of major depressive disorder (MDD) is
associated with higher rates of cardiac complications (such as
reinfarction and the need for revascularization) [3] and a two-to-four
times increased risk of cardiac mortality compared with non-
depressed patients [4–6]. Recently, the INTERHEART study
reported an increase risk of acute MI across a variety of psychosocial
stressors, including depression, in a large, multinational, case-control
study [8]. Given that the World Health Organization Global Burden
of Disease Survey estimates that by the year 2020, coronary heart
disease and depression will be the first and second most disabling
conditions worldwide, respectively, understanding the relationships
between these disorders is critical [9].
A number of mechanisms underlying the link between stress,
depression and cardiovascular disease have been proposed (for a
comprehensive review, see reference [10]). Stress-related changes
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in sympathetically mediated hemorheologic factors related to
blood viscosity and hemoconcentration, such as hematocrit and
total plasma protein, may provide a link between behavioral stress
and the development of CVD [11]. Increased blood viscosity has
been associated with cardiac ischemia, myocardial infarction and
necrosis, and stroke [12–14]. Hemoconcentration increases the
risk of ischemia and thrombosis [15,16], and increased levels of
hematocrit and hemoglobin have been identified as independent
risk factors for CVD [17].
Behavioral/emotional stress and chronic anxiety have been
shown to cause changes in hemorheologic measures, possibly due
to increases in catecholamines and blood pressure [18]. These
changes have been referred to variably as stress-hemoconcentra-
tion, stress polycythemia, relative polycythemia, pseudopolycythe-
mia, or spurious polycythemia and are characterized by an
increased red-cell-mass-to-plasma ratio resulting from a reduction
in plasma volume in the presence of normal red cell counts. Shifts
of fluids out of the blood and into other compartments of the body
are responsible for this manifestation of hemoconcentration [18].
Several studies have documented hemoconcentration in response
to acute mental or psychomotor challenges. Maes et al. studied
students under two baseline conditions, a few weeks before and
after a difficult exam, and the day before the stressor, and reported
significant stress-induced hematological changes [19]. Others have
looked at more acute stress tasks (3–20 minutes) in the laboratory
and report changes consistent with hemoconcentration [20–22].
Such findings have implications for cardiovascular disease risk in
acute and chronic stress.
Despite the importance of the hemorheologic changes described
in stress-hemoconcentration and the overlap between stress and
depression in studies of cardiovascular disease risk, such changes
have not been systematically studied in MDD. The present study is
a secondary analysis of data from a randomized, double-blind trial
of fluoxetine versus desipramine in a group of outpatients with
mild to moderate MDD before and after antidepressant treatment
compared to a group of ethnically-matched controls. The primary
analysis focused on genetic markers of depression and antidepres-
sant treatment response and has been reported elsewhere [23] Our
hypothesis for the secondary analysis presented in this paper was
that subjects with MDD would exhibit hematological and
hemorheologic measures compatible with stress-hemoconcentra-
tion, and that these measures would improve with successful
antidepressant treatment.
Methods
Study population
This study was approved by the University of California, Los
Angeles (UCLA) and University of Miami (UM) IRBs and has
been registered in the public database clinicaltrials.gov
(NCT00265291). The study population consisted of control and
MDD individuals. All subjects gave written informed consent and
received comprehensive psychiatric and medical assessment. We
used diagnostic and ratings instruments that have been fully
validated in English and in Spanish, and conducted all assessments
in the subject’s primary language.
We studied 146 outpatient depressed subjects, all of whom were
Mexican-Americans (defined as having at least 3 grandparents born
in Mexico) aged 19–65 years, who were participating in an ongoing
randomized, double-blind pharmacogenetic study of antidepressant
response to desipramine or fluoxetine and completed the 8-week
treatment trial (see Table 1 for population characteristics). All
depressed subjects had a current episode of unipolar major
depression as diagnosed by the Structured Clinical Interview for
DSM-IV (SCID). Severity of depression was assessed with the 21-
Item Hamilton Depression Rating Scale (HAM-D21) [24]; a score of
18 or greater, with item number 1 (depressed mood) rated 2 or
greater, was required for inclusion. The SCID and HAM-D21 have
been validated in English and Spanish, and all assessments were
conducted in the subject’s primary language. Exclusion criteria
included any primary Axis I disorder other than MDD (e.g.
dementia, psychotic illness, bipolar disorder, adjustment disorder);
electroconvulsive therapy in the last 6 months; previous lack of
response to desipramine or fluoxetine; current, active suicidal
ideation with a plan and strong intent; or any other antidepressant
treatment within the 2 weeks prior to enrollment. Patients enrolled in
this protocol were either drug-naı¨ve or drug-free for at least two
weeks; in that case, their antidepressant medication had been
discontinued for clinical reasons or because of non-adherence.
Subjects with any active medical illnesses that could be etiologically
related to the ongoing depressive episode (e.g. untreated hypothy-
roidism, cardiovascular accident within the past 6 months,
uncontrolled hypertension or diabetes), and who were pregnant,
lactating, currently using medications with significant central
nervous system activity (e.g. benzodiazepines), exhibiting illicit drug
use and/or alcohol abuse in the last 3 months, or currently enrolled
in psychotherapy were also excluded. Female patients were required
to use contraception during our treatment trial, but only 4 used
hormonal contraceptive agents. Our patients were predominantly
non-smokers (only 6 were smokers), and 37 patients were taking
other medications during our trial.
We studied 46 ethnically-matched control subjects (Table 1)
who were recruited from the same Mexican-American Los
Angeles community and evaluated by the same bilingual, clinical
research team at the Center for Pharmacogenomics and Clinical
Pharmacology, David Geffen School of Medicine at UCLA [25].
Control subjects were in good general health and free of ongoing
physical illness. They showed no evidence of major psychiatric
illness in clinical and structured interview. Control and MDD
individuals received the same comprehensive psychiatric and
medical assessments.
Table 1. Demographic Data and BMI for Controls and MDD
Subjects
Subject* Gender{ N (%) Variable{ Mean6SD
Controls Female 33 (72) Age 35.968.9
BMI 28.664.5
Male 13 (28) Age 33.267.7
BMI 29.464.6
All 46 Age 35.268.6
BMI 28.864.5
MDD Subjects Female 97 (66) Age 36.469.7
BMI 28.365.6
Male 49 (34) Age 38.969.5
BMI 28.264.0
All 146 Age 37.269.7
BMI 28.365.1
*p for unpaired t-test is 0.194 for age and 0.543 for BMI between controls and
MDD patients.
{p for Chi-square test is 0.503 for gender ratio between controls and MDD
patients.
{Age in year; BMI: body mass index defined as weight in kilogram divided by
the square of height in meters.
doi:10.1371/journal.pone.0002350.t001
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Antidepressant treatment
All MDD subjects reported here completed 8 weeks of a
randomized, double-blind trial of antidepressant treatment
response to desipramine or fluoxetine as part of a pharmacoge-
netic study. The treatment had two phases. Phase 1 was a 1-week,
single-blind placebo lead-in phase to eliminate placebo responders.
Subjects who continued to meet the inclusion criteria after Phase 1
were randomly assigned to one of two treatment groups in a
double-blind manner in Phase 2 during which they received
fluoxetine 10–40 mg/day or desipramine 50–200 mg/day, for 8
weeks, with a dose escalation based on clinical outcomes. All
subjects had 9 weeks of structured follow-up assessments. Our
primary clinical outcome measure within the depressed group
receiving antidepressant treatment was the HAM-D21. Remitter
was defined as the patients who had a final HAM-D21 score ,8.
Hemorheologic measures
Blood was collected from a vein in the antecubital fossa before
beginning antidepressant treatment (week 22) and at the end of
treatment (week 8). All samples were drawn after the subjects had
rested in a supine position for 5–10 minutes. Samples for white blood
cell (WBC) and red blood cell (RBC) count, hematocrit (HCT) and
hemoglobin (HGB) levels were drawn into 7 ml ethylenediaminetet-
raacetic acid (K2 EDTA) BD-Vacutainer
H tubes. Total serum protein
(TSP) and albumin samples were drawn into chilled 7-ml K2 EDTA-
treated BD-VacutainerH tubes and placed on ice until centrifuged at
3000 rpm for 10 minutes at 4uC. Blood count and protein analysis
were performed by the UCLA Clinical Laboratories and Pathology
Services using a Sysmex XE-2100 (Sysmex Co, Kobe, Japan) and
Synchron LXH20 (Beckman Coulter, Fullerton, CA), respectively.
Whole Blood Viscosity (WBV) Estimation
WBV was determined in centipoises (cP) at a shear rate of 208
seconds21 using the following equation: WBV = 0.126HCT
(%)+0.176serum proteins (g/dL)
This equation has been validated by de Simone et al [26]. By
comparison with direct WBV measurements (r = 0.92, n = 50) in
adults.
Plasma Volume Estimation
Estimates in plasma volume changes before and after 8-weeks
antidepressant treatment was calculated using the following formula:
PvolT~ 100| HgbB=HgbAð Þ½ {
100| HgbB=HgbAð Þð Þ| HctA=100½ ,
where PvolT is the plasma volume after antidepressant treatment,
HgbB is the hemoglobin before treatment (at 22 week), HgbA and
HctA are the hemoglobin and hematocrit after 8-week treatment,
respectively [27].
Statistical Analyses
Variables used for secondary data analyses included HAM-D21
scores and the following measurements: RBC, HGB, HCT, WBC,
TSP, albumin levels and estimation of WBV. MDD subjects were
analyzed before (week22) and after treatment (week 8), and control
subjects were measured at one time point for comparison.
To assess similarity between depressed and control subjects,
unpaired t-tests were used to compare age and BMI means and a x2
test was used to compare gender ratios. To examine the potential
effects of gender and age, unpaired t-tests were also performed for
the difference in blood measurements between female and male, and
Pearson correlation analysis was conducted for the correlation of age
with blood measurements. To adjust for gender and age, a general
linear model (GLM) was employed to conduct multivariate tests
(MANOVA) to compare blood measurements between MDD
subjects and controls or between desipramine- and fluoxetine-
treated MDD subjects. Paired T-tests were used to compare blood
measurements before and after treatment in MDD subjects.
Spearman partial correlation was used to measure the degree of
association of HAM-D21 score with the blood measurements by
controlling for age and gender. Stepwise logistic regression analysis
was conducted to screen the predictors that allow a differentiation
between remitter and non-remitter patients using the baseline HAM-
D21 score, baseline blood measurements, antidepressant medica-
tion, age, and gender variables.
All analyses were performed using SPSS version 14.0 (SPSS
Inc., Chicago, IL, USA), except for Spearman partial correlation
analysis which was conducted with SAS version 9.1 (SAS Institute
Inc., Cary, NC, USA). As HAM-D21 score is an ordinal
measurement rated on a 5-point scale for each item (from ‘‘0 –
not present’’ to ‘‘4 – severe’’) and did not follow normal
distribution when used as an interval variable, Spearman partial
correlation was used. A significance level of 0.05 was used for all
statistical testing, and the Bonferroni post-hoc method of
correction was used to correct for multiple testing.
Role of Funding Sources:
This study was funded by the National Institute of General
Medical Sciences (NIGMS), the National Institute of Diabetes and
Digestive and Kidney Diseases (NIDDK), and the National Center
for Research Resources (NCRR). The sponsors were not involved
in the study design; the collection analysis and interpretation of
data; the writing of the report; or the decision to publish.
Results
Hemorheologic and Hematological Measures in MDD
Subjects and Controls
Our data are compatible with classical findings that gender
influences red blood cell (RBC) measurements and albumin levels.
RBC measurements are correlated with gender; female subjects
had lower RBC count (p,0.0001; 4.560.36106/ mL in females vs
5.160.46106/ mL in males), lower HGB levels (p,0.0001;
13.261.1 g/dL in females vs 15.361.0 g/dL in males) and lower
albumin levels (p = 0.0004; 4.160.3 g/dL in females vs 4.3 g/
dL60.3 g/dL in males). The results of correlation analysis showed
that age was conversely correlated with TSP (r =20.17, p = 0.019)
and albumin (r =20.18, p = 0.012).
Therefore, we performed multivariate analysis of variance
(MANOVA) to compare group differences in hemorheologic
measures and WBC count by controlling for gender and age
(Table 2). Our results showed that before treatment, MDD subjects
had significantly increased hemorheologic measures in total RBC
count (p = 0.048), HBG (p = 0.005), HCT (p = 0.001), TSP concen-
trations (p = 0.010), and total WBC count (p = 0.039). Albumin levels
showed a trend towards an increase when compared to controls
(p = 0.052). MDD subjects also had higher estimated WBV than
controls (p,0.001). After treatment, no significant differences in the
hemorheologic measures or WBC count were found between MDD
subjects and controls (all p values$0.088).
Hemorheologic Measures in MDD Subjects Before and
After Antidepressant Treatment
In MDD subjects, hemorheologic parameters of stress-hemo-
concentration improved after 8 weeks of antidepressant treatment
Stress in Major Depression
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(Table 3). Paired t-test analyses showed that all the six
hemorheologic measures and the WBC count in MDD subjects
decreased significantly after antidepressant treatment (p#0.0003).
Hemorheologic Measures in Desipramine- and
Fluoxetine- Treated MDD Subjects
Measures of stress-hemoconcentration were not significantly
different in subjects treated with desipramine or fluoxetine in
MANOVA analysis. Our analyses showed that total RBC count,
HBG, HCT, total WBC, TSP and albumin did not differ between
the two groups in the final week of treatment.
Hemorheologic Measures and HAM-D21 Score in MDD
Subjects
Table 4 presents the results of Spearman partial correlation
analyses by controlling for age and gender. Our data showed that
before treatment, hemorheologic measures were correlated with
HAM-D21 score with a correlation coefficient of 0.21 for WBC
count (p = 0.01), 0.18 for RBC count (p = 0.027), 0.24 for HCT
(p = 0.003), 0.29 for WBV (p,0.001), and 0.22 for albumin level
(p = 0.009). Our data also showed that improvements in WBC count,
RBC measures, and plasma volume percentage were positively
correlated with the improvement in HAM-D21 score, although no
statistical significant difference was found for the change in
hemorheologic measures between remitters and non-remitters.
Baseline Hemorheologic Measures and Clinical Remission
Status
Stepwise logistic regression analysis revealed that the significant
predictors of remission included HAM-D21 score (OR = 0.85,
95%CI = 0.77–0.93, p = 0.0003), TSP (OR = 2.81, 95%CI = 1.03–
7.67, p = 0.044) and albumin (OR = 0.13, 95%CI = 0.02–0.67,
p = 0.015) at baseline. Taking together, the model yielded a 73%
concordance between the observed and predicted remission status.
Discussion
Our secondary data analyses indicate that hemorheologic
measures of stress-hemoconcentration are present in Mexican-
American individuals with mild to moderate MDD and that these
measures decrease significantly after 8 weeks of antidepressant
treatment to levels which were the same as those of controls.
Measures we obtained in depressed subjects at rest (in the absence
of any deliberate psychological challenge) are comparable to those
elicited after a stressful challenge in other studies [19–22]. We
propose that stress-hemoconcentration may contribute to the
increased risk of CVD found in MDD.
Table 2. Hemorheologic Measures and WBC Count in MDD
Subjects before Treatment (week 22) and Controls
Hemorheologic Measures
Controls
(N=46)*
MDD Subjects
(N=146)* p{
RBC count 2106/mL 4.660.5 4.760.4 0.048
HGB – g/dL 13.461.6 14.061.4 0.005
HCT 2% 39.564.2 41.463.5 0.001
TSP – g/dL 7.160.5 7.360.5 0.010
Albumin – g/dL 4.160.4 4.260.3 0.052
WBV – cP 5.960.5 6.260.4 ,0.001
WBC count 2106/mL 6.861.5 7.562.1 0.052
*Values are means6SD.
{p was based on MANOVA using GLM model by adjusting for age and gender.
doi:10.1371/journal.pone.0002350.t002
Table 3. Hemorheologic Measures and WBC Count in MDD
Subjects before (week 22) and after (week 8) Treatment
Hemorheologic
Measures
Number of
Patients*
Before
Treatment#
After
Treatment# p{
RBC count 2106/mL 146 4.760.4 4.660.4 0.0003
HGB – g/dL 146 14.061.4 13.861.4 ,0.0001
HCT 2% 146 41.463.5 40.663.6 ,0.0001
TSP – g/dL 146 7.360.5 7.160.4 ,0.0001
Albumin – g/dL 146 4.260.3 4.060.3 ,0.0001
WBV – cP 146 6.260.4 6.160.5 ,0.0001
WBC count 2106/mL 146 7.562.1 6.761.7 ,0.0001
*Subjects with no missing data.
#Values are means6SD.
{p was based on paired t-test.
doi:10.1371/journal.pone.0002350.t003
Table 4. Correlations of HAM-D21 Score, Hemorheologic Measures and WBC Count in MDD Subjects (N= 146)
Hemorheologic Measures
before Treatment HAM-D21 Score before Treatment
Change in Hemorheologic
Measures with treatment Change in HAM-D21 Score
r p{ r p{
RBC count 2106/mL 0.18 0.027 RBC count 2106/mL 0.22 0.008
HGB – g/dL 0.14 0.105 HGB – g/dL 0.18 0.027
HCT 2% 0.24 0.003 HCT 2% 0.22 0.008
TSP – g/dL 0.26 0.002 TSP – g/dL 0.14 0.086
Albumin – g/dL 0.22 0.009 Albumin – g/dL 0.13 0.115
WBV – cP 0.29 ,0.001 WBV – cP 0.21 0.010
Plasma volume" 0.20 0.017
WBC count 2106/mL 0.21 0.010 WBC count 2106/mL 0.23 0.007
{p was based on Spearman partial correlation by controlling for age and gender.
"Plasma volume change % after treatment based on the method provided by Dill and Costill.27
doi:10.1371/journal.pone.0002350.t004
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Psychological stress has been identified as a risk factor for CVD,
as a trigger of acute coronary events, and as a contributor to the
pathogenesis of atherosclerosis and hypertension [10]. Thus, given
our findings of stress-hemoconcentration at rest in MDD, this
mechanism is also a potential link in the association of MDD and
CVD. In MDD, stress-hemoconcentration may increase blood
viscosity; this may lead to a decrease in pressure at vulnerable
branching sites of coronary arteries and increased exposure time to
atherogenic substances [18].
During stress, hemoconcentration can be at least partially
explained by sympathetic nervous system activation (for a
comprehensive review see reference [22]. Infusion of catechol-
amines has been shown to result in reductions of plasma volume
with parallel rises in hematocrit, possibly due to increases in
systemic pressure and capillary hydrostatic pressure that reflects
passive movement of fluid out of the capillaries. Elevations in
plasma catecholamines have also been described in MDD [28]
and thus, sympathetic nervous system activation would also be a
valid explanation for alterations of stress-hemoconcentration
measures in MDD, but in this study we have not obtained
concomitant measures of plasma catecholamines; therefore, this
possible relationship remains to be directly documented.
Stress hemoconcentration has not been systematically studied in
MDD. Several studies on relatively small numbers of depressed
subjects (30–50) examining other systemic aspects of depression –
inflammation and the acute phase response – have reported on some
measures that overlap with those we examined. Total serum protein
[29], albumin [30], as well as RBC, HGB and HCT [31] have been
reported as decreased in depression, unlike the increase we report in
our population. Several major differences exist between these studies
and ours, the most significant being that the studies were all
conducted on smaller, acute inpatient populations. Multiple factors
may differentiate inpatients with depression from outpatients: higher
severity of illness, with the possibility of decreased mobility and poor
nutritional status, and greater duration of illness with more exposure
to medication. We examined several potential confounds in our
study and found no difference in our results if we eliminated
individuals with history of cardiovascular problems (n = 8) or family
history of cardiac problems (n = 17) or individuals taking other
medication (n = 37) or using hormonal contraceptive agents (n = 4)
or smoking (n = 6). One limitation of the current study is that we did
not directly measure fluid and food intake; another is that we did not
collect the information on smoking habits for all the patients and
controls. No significant weight change was observed over the course
of the study, and while the appetite item on the Beck Depression
Inventory did show improvement, there was no significant
correlation between appetite score change and change in hemocon-
centration measures. A strength of our study is the focus on one
ethnic group with strict inclusion criteria (3 of 4 grandparents born in
Mexico), thus minimizing variation that could be introduced by a
genetically more heterogenous population. It is unknown whether
other ethnic groups could react differently.
Importantly, the changes in hemorheologic measures that we
report in our depressed subjects improved with treatment.
Treatment of depression has been reported to lessen the risk of
MI associated with depression [32,33], and MDD patients
adequately treated have lower heart disease mortality than
inadequately treated depressed patients [33]. The use of
antidepressants remains controversial in CVD, especially the use
of tricyclic antidepressant medications because they could be
associated with an increase risk of CVD [34]. Roose et al. [35]
have reported in a small controlled trial that paroxetine and
nortriptyline are effective treatments for MDD patients with
ischemic heart disease. A randomized clinical trial showed that
selective serotonin reuptake inhibitor (SSRI) sertraline was safe
and effective in treating recurrent depression in patients with an
acute MI or unstable angina and without other life-threatening
medical conditions [36]. Emerging evidence shows that treatment
of MDD patients who experience an acute MI with SSRI
antidepressants might decrease mortality or cardiac events [37].
There is evidence that lower adherence to prescribed medications
and cardiac prevention measures is present in post-MI patients
with depression [38] and that treatment of MDD could improve
compliance with CVD treatment. In this study, we examined both
a tricyclic and an SSRI antidepressant. Our response rates, which
were higher than in some other antidepressant trials, may reflect
the fact that placebo responders were eliminated after the first
week and that our patients were from a previously untreated,
community-based population. A potential concern was the
possibility of orthostatic hypotension with desipramine, and
subjects in this treatment group did demonstrate more orthostasis
by pulse than those treated with fluoxetine (data not shown).
However, as described, all of our samples were taken after 5–
10 minutes of supine rest. No difference was observed in treatment
response or in hemorheologic measures between the two drugs.
Figure 1 gives a brief overview on how we could integrate data on
acute stress-hemoconcentration and MDD.
Our data based on secoondary analyses support the notion that
successful antidepressant treatment ameliorates hemorheologic
measures of stress-hemoconcentration, which indicates that factors
consistent with increased blood viscosity and the advancement of
atherosclerotic plaque in low-pressure sites in the arterial tree may
be alleviated following the improvement of MDD symptomatol-
ogy. Our results suggest that hemorheologic changes in patients
suffering from MDD could contribute to an increased risk for
CVD. Antidepressant treatment reduces not only the psycholog-
ical symptoms of depression, but it also may reduce this potentially
important depression-associated risk factor for CVD. Hemorheo-
logic measures of stress-hemoconcentration are of low cost and
often contained in routine lab assessments, but they have not yet
been considered as a relevant biomarker of CVD risk in
depression. We suggest here that physicians who assess major
depression and provide antidepressant treatment should consider
stress hemoconcentration when evaluating the cardiovascular risk
factors of depressed patients.
Figure 1. Relationship between acute stress, stress-hemocon-
centration and MDD. Normal individuals can display hemorheologic
measures of stress-hemoconcentration after acute psychological stress.
Those measures return to baseline levels within minutes after the stress
situation is terminated. Subjects with major depressive disorder (MDD)
display stress-hemoconcentration at baseline, non-stressed conditions
and those measures return to baseline levels in responders to an 8-
week treatment with antidepressants.
doi:10.1371/journal.pone.0002350.g001
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Supporting Information
Protocol S1 Trial Protocol
Found at: doi:10.1371/journal.pone.0002350.s001 (0.06 MB
PDF)
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